Bacillus Calmette-Guerin Substrain Tice Live Antigen
- Vaccine
- Still being tested
- Identity checked
- Sources last checked 2026-09-04
This page shows what was measured, who it was measured in, and what that does not settle.
RNAWiki holds very little about this substance. The page shows what there is.
What Bacillus Calmette-Guerin Substrain Tice Live Antigen does in the body
TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence.
From the FDA-approved label: TICE ® BCG induces a granulomatous reaction at the local site of administration. Intravesical TICE BCG has been used as a therapy for, and prophylaxis against, recurrent tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage TaT1 papillary tumors of the bladder at high risk of recurrence. The precise mechanism of action is unknown.
Why people take it. TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
- Where it acts
- Not recorded.
- Kind of result
- No result is published, so no kind of result applies yet
- Supervision
- Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as structurallydiverse.
FDA substance registry · 2XQ558L16Z · read 2026-08-29
It is recorded as coming from MYCOBACTERIUM BOVIS BCG. The part recorded is whole.
FDA substance registry · 2XQ558L16Z · read 2026-08-29
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 197 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What is missing or unclearRead from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
- TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence.
Who is missing from the studies
- Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness of TICE BCG for the treatment of superficial bladder cancer in pediatric patients have not been established.”
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-30
On older people, the label states: “Of the total number of subjects in clinical studies of TICE BCG, the average age was 66 years old.”
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-30
On people who are pregnant, the label states: “Animal reproduction studies have not been conducted with TICE BCG.”
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-30
On people who are breastfeeding, the label states: “It is not known whether TICE BCG is excreted in human milk.”
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-30
Where the result stopped carrying
- This is a scope explorer, not a diagnosis engine.
- It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to takeRead from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
- It was studied for a different goal
- The studies measured something else entirely. Nothing in this record points to this reason.
- A different form was studied
- The studied form is not the form on the shelf. Nothing in this record points to this reason.
- There was nothing to correct
- Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
- Something else had to happen too
- In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
- The change is too small to feel
- A real change can still sit below what a person notices. Nothing in this record points to this reason.
- Day-to-day swing hides it
- Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
- Not enough time yet
- The studies ran longer than the person has waited. Nothing in this record points to this reason.
- It was not taken as studied
- Missed days change the result, and studies count them. Nothing in this record points to this reason.
- Something else changed at the same time
- Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
- The product may not be what it says
- Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
- No recorded reason
- RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to takeRead from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Still being tested
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Percutaneous
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S6.
No source is stored against this line.
What is in the pack
Sold as injection, powder, lyophilized, for solution, powder, for suspension, given by the percutaneous, intravesical route.
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to takeNothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclearRead from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Percutaneous
Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
2 products list this as an active ingredient in the United States drug directory. 2 of them contain it and nothing else.
FDA National Drug Code directory · 0052-0602 · read 2026-08-29
They are sold as injection, powder, lyophilized, for solution and powder, for suspension, taken intravesical and percutaneous.
FDA National Drug Code directory · 0052-0602 · read 2026-08-29
The regulator's established pharmacologic class for it is actively acquired immunity [pe], attenuated [cs] and bcg vaccine [cs].
FDA National Drug Code directory · 0052-0602 · read 2026-08-29
1 published label names it as an active ingredient. 1 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-29
3269 marketed supplement labels list this ingredient, classed as botanical, non-nutrient/non-botanical and other combinations.
NIH Dietary Supplement Label Database · 210832 · read 2026-08-29
Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
NIH Dietary Supplement Label Database · 210832 · read 2026-08-29
TICE BCG is intravesical at HOW SUPPLIED TICE ® BCG is supplied in a box of 1 single-dose vial of TICE BCG., recorded as fda label in effect 2026-02-20 in the United States.
US prescribing information · c9b74876-e665-442b-87ad-b7333bc9a67a · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to takeRead from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine, investigational agent. The questions below are for a clinician or pharmacist.
Questions worth asking
- Which of the trials of Bacillus Calmette-Guerin Substrain Tice Live Antigen studied people like me?
- What was measured, and for how long?
- Was the result a laboratory value or a health outcome?
- What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclearRead from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How much did people take in the studies?
The sources RNAWiki checked hold nothing for this field.
Why it matters. A result belongs to an amount. Without the amount the result floats free.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Bacillus Calmette-Guerin Substrain Tice Live Antigen are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in peopleRead from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Where else this substance is registered
- FDA substance identifier (UNII)
- 2XQ558L16Z
- RxNorm concept
- 221050
- DrugBank
- DB10343
Checks this page had to pass
Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Passed
Safety mode resolved
Suppression classes recorded: S6.
Passed
Canonical metadata present
slug and display name present
What is missing or unclearRead from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
The earliest marketing start date recorded for a listed product is 19890621.
FDA National Drug Code directory · 0052-0602 · read 2026-08-29
What is missing or unclearRead from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
- Were people like me actually studied?
- How close is this evidence to something I would notice?
- What does nobody know about this yet?
- What is a biomarker?
This order is fixed in code and does not count clicks or time on the page.
What is not here
10 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
- What was measured, goal by goal — found nothing in the sources checked.
- What happened in people — found nothing in the sources checked.
- How close this is to real life — found nothing in the sources checked.
- The path through the body — found nothing in the sources checked.
- Felt, measured, or meaningful — found nothing in the sources checked.
- How long anything takes — found nothing in the sources checked.
- What it may clash with — found nothing in the sources checked.
- Other ways to the same goal — found nothing in the sources checked.
- Claims that go past the evidence — found nothing in the sources checked.
- What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (8)
On the Bacillus Calmette-Guerin Substrain Tice Live Antigen label: indicated for what?
"TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they…": indications and usage on Bacillus Calmette-Guerin Substrain Tice Live Antigen's label. DailyMed label · c9b74876-e665-442b-87ad-b7333bc9a67a · 2026-02-20
75 registered trials of Bacillus Calmette-Guerin Substrain Tice Live Antigen — at which phases?
- Registered studies posting no result
- 64 of 75
75 registered studies of Bacillus Calmette-Guerin Substrain Tice Live Antigen: 27 phase3, 21 phase2, 16 phase4, 11 phase1, 3 early phase1, 3 na, 1 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01
0 with a PubMed record
Show the evidence
- phase327
- phase221
- phase416
- phase111
- early phase13
- na3
9 more recorded rows
- na or unstated1
- completed38
- unknown10
- active not recruiting8
- recruiting6
- terminated6
- withdrawn4
- enrolling by invitation2
- suspended1
recorded 2026-09-01 · last checked 2026-09-04
10 of Bacillus Calmette-Guerin Substrain Tice Live Antigen's trials stopped: accrual/recruitment, other?
accrual/recruitment (4) and other (6): Bacillus Calmette-Guerin Substrain Tice Live Antigen's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated"; 10 of 75 registered studies
Show the evidence
Trial
- NCT00003715terminated; "Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated"
- NCT00352079terminated; "terminated due to poor accrual"
- NCT00974818terminated; "Lack of accrual"
- NCT01284205withdrawn; "This indication is not being pursued at this point in time."
- NCT02010203terminated; "Inability to accrue due to changing treatment landscape (PD-1 approvals)"
- NCT04453293terminated; "The sponsor has elected to discontinue/terminate the study prematurely due to slower-than-anticipated recruitment and limited remaining research funding."
4 further recorded trials
- NCT04534803withdrawn; "At this time it has been decided by the study team the the study will no longer take place in the United States."
- NCT04938323withdrawn; "Covid-19 related delays in project launch"
- NCT05330884suspended; "changes in protocol"
- NCT05539989withdrawn; "The study is no longer moving forward due to the changing TB vaccine landscape."
recorded 2026-09-01 · last checked 2026-09-04
Which running trial of Bacillus Calmette-Guerin Substrain Tice Live Antigen could settle lifespan?
NCT04165317 measures Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C, reading out 2026-12-02.
4 open trials; n 1068; "A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer"
Show the evidence
Trial
- NCT04165317"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer"; n 1068; "Cohort A: Event Free Survival (EFS) as Assessed by the Investigator: Arm A Versus Arm C"; 2026-12-02
- NCT03528694"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer"; n 1018; "The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC"; 2028-10-03
- NCT07000084"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy"; n 330; "High Grade Recurrence-free survival (HG-RFS)"; 2028-12-05
- NCT05538663"Intravesical BCG vs GEMDOCE in NMIBC"; n 870; "Event-Free Survival"; 2030-10
Which 22 trials of Bacillus Calmette-Guerin Substrain Tice Live Antigen posted no result?
- Posted no result
- 22 of 22 completed trials
- Registrations
- NCT01442519, NCT00003759, NCT00003184, NCT00016133, NCT00427570 and NCT01697306, and 16 more
- Completion dates
- oldest 2002-06; newest 2024-08-18
Show the evidence
Trial
- NCT014425192002-06
- NCT000037592002-11
- NCT000031842003-07
- NCT000161332004-08
- NCT004275702006-05
- NCT016973062012-05
14 further recorded trials
- NCT020855902014-11
- NCT023893222015-09
- NCT023261682015-10
- NCT024135022015-10
- NCT006949152015-10-07
- NCT021754202015-11
- NCT024446112016-06
- NCT027952602016-10
- NCT018781882017-10
- NCT020021562018-06-27
- NCT043284412021-03-31
- NCT044142672021-05-07
- NCT044753022021-09-20
- NCT043272062022-05-27
At the median, Bacillus Calmette-Guerin Substrain Tice Live Antigen's trials enrolled 120 people — anything larger?
- Median enrolment
- 120
- Largest enrolment
- 9200
- Registered trials counted
- 67
What do 552 spontaneous reports say about Bacillus Calmette-Guerin Substrain Tice Live Antigen — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Bacillus Calmette-Guerin Substrain Tice Live Antigen appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 552 reaction mentions were counted: bladder cancer recurrent 124; product availability issue 91; disseminated bacillus calmette-guerin infection 76; pyrexia 66. FAERS via Open Targets · CHEMBL2108020 · 2026-06-24
Show the evidence
- bladder cancer recurrent124
- product availability issue91
- disseminated bacillus calmette-guerin infection76
- pyrexia66
- occupational exposure to product38
- cystitis36
4 more recorded rows
- haematuria36
- chills30
- dysuria30
- treatment failure25
recorded 2026-06-24 · last checked 2026-09-04
Which 10 reactions does Bacillus Calmette-Guerin Substrain Tice Live Antigen's label not list?
bladder cancer recurrent, chills and cystitis and 7 more reported for Bacillus Calmette-Guerin Substrain Tice Live Antigen, absent from its label. FAERS via Open Targets · CHEMBL2108020 · 2026-06-24
2 label terms; 10 reported and unlisted; c9b74876-e665-442b-87ad-b7333bc9a67a
Show the evidence
- bladder cancer recurrentcount not stated
- chillscount not stated
- cystitiscount not stated
- disseminated bacillus calmette-guerin infectioncount not stated
- dysuriacount not stated
- haematuriacount not stated
4 more recorded rows
- occupational exposure to productcount not stated
- product availability issuecount not stated
- pyrexiacount not stated
- treatment failurecount not stated
recorded 2026-06-24 · last checked 2026-09-04
Where it is registered
Identifiers, relations and other names
The exact record
- UNII
- 2XQ558L16Z
- ChEMBL id
- CHEMBL2108020
- RxCUI
- 221050
- Also called
- BCG LIVE, Bcg vaccine live intradermal (tice), bacillus calmette-guérin, bcg, BACILLE CALMETTE-GUERIN (BCG) VACCINE TICE STRAIN, BACILLUS CALMETTE-GUERIN (BCG) LIVE, BACILLUS CALMETTE-GUERIN (BCG) STRAIN TICE, BACILLUS CALMETTE-GUERIN STRAIN TICE LIVE ANTIGEN, BACILLUS CALMETTE-GUERIN,TICE VACCINE, BACILLUS CALMETTE-GUERIN,TICE VACCINE [VANDF], BCG LIVE INTRAVESICAL
- Trade name
- Tice bcg, BCG Vaccine, BCG Vaccine / Tice BCG
- Salt form
- BACILLUS CALMETTE-GUERIN
Sources (4)
Sources
- CLINICALTRIALS_SNAPSHOT K1:2XQ558L16Z ·
- DailyMed label c9b74876-e665-442b-87ad-b7333bc9a67a ·
- FAERS via Open Targets CHEMBL2108020 ·
- Drugs@FDA K1:2XQ558L16Z ·
ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
How these records are assembled · Which registers were checked
Index-quality checks
- identity passed: no open identity hold
- required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
- public claims reviewed: 0 reviewed claim(s); drafts are never rendered
- source coverage passed: 4 source rows
- no critical contamination: no quarantine open
- canonical metadata passed: slug and display name present
- no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.